Nanoparticle-directed tissue-specific delivery system for genes and drugs

Area of Science:

• Biotechnology
• Molecular Biology
• Medical Science

Background:

• Gene therapy offers potential treatments for monogenic diseases, infectious diseases, and cancer.
• Conventional gene therapy relies on virus-based vectors (e.g., adenovirus, retrovirus, lentivirus, adeno-associated virus).
• Current viral vectors face challenges including off-target tissue distribution, potential for side effects, and limitations in gene size capacity.

Purpose of the Study:

• To highlight the critical need for targeted in vivo gene delivery in next-generation gene therapy.
• To address the limitations associated with conventional viral vectors.
• To improve the safety and efficacy of gene therapy applications.

Main Methods:

• Review of existing literature on gene therapy vectors.
• Analysis of challenges in current viral vector technology.
• Discussion of the importance of in vivo targeting strategies.

Main Results:

• Conventional viral vectors exhibit poor in vivo targeting, leading to unintended gene expression and side effects.
• Limitations include restricted therapeutic gene size and potential integration into the host genome.
• Manufacturing viral vectors is hazardous and costly due to high, non-specific infectivity.

Conclusions:

• In vivo targeting of therapeutic genes is a paramount concern for advancing gene therapy.
• Overcoming current vector limitations is essential for developing safer, more effective, and cost-efficient gene therapy treatments.
• Future gene therapy strategies must prioritize precise delivery to target tissues.